New Pentasaccharides for the Prophylaxis of Venous Thromboembolism: Clinical Studies

Chest

Volumn 124, Issue 6 SUPPL., 2003, Pages 371S-378S

  Turpie, Alexander G G ^a,e   Eriksson, Bengt I ^b   Bauer, Kenneth A ^c   Lassen, Michael R ^d  

^a HAMILTON GENERAL HOSPITAL   (Canada)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Deep vein thrombosis; Enoxaparin; Fondaparinux; Low molecular weight heparin; Orthopedic surgery; Pentasaccharide; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; FONDAPARINUX; PENTASACCHARIDE;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ELECTIVE SURGERY; HIP FRACTURE; HUMAN; INCIDENCE; KNEE SURGERY; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK; TOTAL HIP PROSTHESIS; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

EID: 0346364794     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Petitou M, Lormeau JC, Choay J. Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs. Nature 1991; 350(suppl):30-33
2. van Boeckel CAA, Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem Int Ed Engl 1993; 32:1671-1690
3. Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91:4197-4205
4. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41(suppl 2):1-9
5. The PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation [abstract]. Blood 2002; 100:301
6. Turpie AGG, Gallus AS, Hoek JA, for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344:619-625
7. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345:1305-1310
8. Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345:1298-1304
9. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359:1715-1720
10. Turpie AGG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-1726
11. Eriksson BI, Lassen MR, the Pentasaccharide in Hip Fracture Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163: 1337-1342
12. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation 2000; 102:2726-2731
13. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor Xa-inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. Eur Heart J 2001; 22:1716-1724
14. Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999; 81:214-220
15. Simmoons M. Oral presentation on the PENTUA clinical trial. Presented at the 74th Annual Scientific Sessions of the American Heart Association, Anaheim CA, November 14, 2001
16. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism: Sixth ACCP Consensus Conference on antithrombotic therapy. Chest 2001; 119(suppl):132S-175S
17. Nicolaides AN. Prevention of venous thromboembolism: international consensus statement; guidelines compiled in accordance with the scientific evidence. Int Angiol 2001; 20:1-37
18. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158:585-593
19. Heit JA, Melton LJ III, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients versus community residents. Mayo Clin Proc 2002; 76:1102-1110
20. Davidson BL. What are the most reliable detection methods for deep vein thrombosis and pulmonary embolism to be used as endpoints in trials of venous thromboprophylaxis? Haemostasis 1998; 28(suppl 3):113-119
21. Kearon C, Julian JA, Math M, et al. Noninvasive diagnosis of deep venous thrombosis. Ann Intern Med 1998; 128:663-677
22. Girard P, Musset D, Parent F, et al. High prevalence of detectable venous thrombosis in patients with acute pulmonary embolism. Chest 1999; 116:903-908
23. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318:1162-1173
24. Leizorovicz A, Haugh MC, Chapuis F-R, et al. Low molecular weight heparin in prevention of postoperative thrombosis. BMJ 1992; 305:913-920
25. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery. Lancet 1992; 340:152-156
26. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prophylaxis of post-operative venous thrombosis and pulmonary embolism by oral anticoagulants: a meta-analysis. Clin Trials Meta-anal 1993; 28:227-240
27. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular- weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83:14-19
28. Mismetti P, Laporte S, Darmon JY, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88:913-930
29. Turpie AGG, Bauer KA, Eriksson BI, et al. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized studies. Arch Intern Med 2002; 162:1833-1840
30. Havig Ö. Deep vein thrombosis and pulmonary embolism: an autopsy study with multiple regression analysis of possible risk factors. Acta Chir Scand 1977; 478(suppl):1-120
31. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 1981; 94:439-444
32. Eriksson BI, Kälebo P, Anthmyr BA, et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement: comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am 1991; 73-A:484-493
33. Kwong LM, Bauer KA, Eriksson BI, et al. Elastic stockings do not influence the superior efficacy of fondaparinux over enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery [abstract]. Presented at XXIIth World Congress of the Société Internationale de Chirurgie Orthopédique et de Traumatologie (SICOT), San Diego, CA, August 23-30, 2002, Abstract Book P2641, 671
34. Eriksson BI, Bauer KA, Lassen MR, et al. Role of the duration of fondaparinux (Arixtra) prophylaxis in preventing venous thromboembolism following major orthopaedic surgery [abstract]. Hematol J 2002; 3(suppl 1):364
35. Hull RD, Brant RF, Pineo GF, et al. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999; 159:137-141
36. Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med 2001; 161:1952-1960
37. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty: a double-blind, randomized comparison. Arch Intern Med 2000; 160:2199-2207
38. Strebel N, Prins M, Agnelli G, et al. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002; 162:1451-1456
39. Turpie AGG, Bauer KA, Eriksson BI, et al. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003; 90:364-366
40. Cohen AT, Bailey CS, Alikhan R, et al. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Thromb Haemost 2001; 85:940-941
41. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358:9-15
42. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001; 135:858-869